Viewing StudyNCT04646044

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 3:28 PM
Last Modification Date: 2024-10-26 @ 1:50 PM
Study NCT ID: NCT04646044
Status: COMPLETED
Last Update Posted: 2024-03-12
First Post: 2020-11-14
Brief Title: A Placebo Controlled Trial of Bempegaldesleukin BEMPEG NKTR-214 With Standard of Care in Patients With Mild COVID-19
Sponsor: Nektar Therapeutics
Organization: Nektar Therapeutics
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Coronavirus Disease 2019
Covid-19
Keywords:
Name View
Severe Acute Respiratory Syndrome Coronavirus 2 View
BEMPEG View
Bempegaldesleukin View
CD122 View
CD122-Biased Agonist View
CD122-Biased Cytokine View
Coronavirus Disease View
COVID-19 View
IL-2 receptor agonist View
Lymphopenia View
Mild COVID View
NKTR-214 View
SARS-CoV-2 View